JADE BIOSCIENCES, INC.
NASDAQ: JBIO (Jade Biosciences, Inc.)
Last update: 8 hours ago10.51
0.03 (0.29%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Jade Biosciences, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 30.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Wedbush, 61.75%) | Buy |
| Median | 15.50 (47.48%) | |
| Low | 14.00 (Guggenheim, 33.21%) | Buy |
| Average | 15.50 (47.48%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 16 Jun 2025 | 14.00 (33.21%) | Buy | 6.99 |
| Wedbush | 15 May 2025 | 17.00 (61.75%) | Buy | 7.40 |
| 07 May 2025 | 17.00 (61.75%) | Buy | 9.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jun 2025 | Announcement | Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy |
| 02 Jun 2025 | Announcement | Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress |
| 14 May 2025 | Announcement | Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 13 May 2025 | Announcement | Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference |
| 21 Apr 2025 | Announcement | Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals |
| 09 Apr 2025 | Announcement | Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
| 07 Apr 2025 | Announcement | Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |